Syros Pharmaceut - SYRS STOCK NEWS

Syros Pharmaceuticals has received Fast Track Designation from the FDA for its drug tamibarotene, aimed at treating higher-risk myelodysplastic syndrome (HR-MDS) with the RARA gene overexpression. This designation highlights the serious unmet medical need for HR-MDS patients, who have a poor prognosis and limited treatment options since 2006. The pivotal SELECT-MDS-1 Phase 3 trial is currently underway, involving 190 patients across 12 countries, with enrollment expected to finish by Q4 2023 and data anticipated in Q3 2024. The company is also exploring tamibarotene's use in combination with other treatments for AML patients.

Syros Pharmaceuticals (NASDAQ:SYRS) announced key updates on its clinical trials and financial position. The company expects to complete enrollment in the SELECT-MDS-1 Phase 3 trial by Q4 2023, with data anticipated by Q3 2024. The SELECT-AML-1 Phase 2 trial is set to initiate its randomized portion in Q1 2023, with initial data expected in Q4 2023. Syros reported strong financial health, with cash sufficient to fund operations into Q2 2025, supporting its strategic focus on developing new treatment standards for hematologic malignancies.

Syros Pharmaceuticals (NASDAQ:SYRS) has granted restricted stock unit (RSU) awards totaling 14,200 shares to four newly hired employees as an inducement for their employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs were awarded on December 22, 2022, and will vest quarterly over four years starting December 31, 2023, contingent on continued employment. Syros focuses on developing gene expression-controlling medicines, with a clinical pipeline including candidates for myelodysplastic syndrome, acute promyelocytic leukemia, and solid tumors.

Syros Pharmaceuticals announced promising results from a Phase 2 trial of tamibarotene combined with azacitidine for treating newly diagnosed, unfit acute myeloid leukemia (AML) patients with RARA overexpression. The trial showed a high complete response (CR) rate of 50% and an overall response rate (ORR) of 67% among those with RARA overexpression. The treatment was generally well tolerated, with no significant added toxicity. Syros is advancing to Phase 3 and Phase 2 trials to further evaluate tamibarotene in myelodysplastic syndrome (MDS) and AML.

Syros Pharmaceuticals (NASDAQ:SYRS) announced promising results from the SELECT-AML-1 Phase 2 trial of tamibarotene for acute myeloid leukemia (AML) patients with RARA gene overexpression. The triplet regimen achieved an 83% composite complete response rate among evaluable patients, significantly surpassing the standard CR rate of 66%. Initial data revealed no increased safety concerns compared to existing treatments. Syros plans to advance to the randomized trial phase in Q1 2023, with results expected in 2023 or 2024.

Syros Pharmaceuticals (NASDAQ:SYRS) announced a virtual event on December 10, 2022, at 12:00 p.m. ET, to discuss initial data from the Phase 2 SELECT-AML-1 clinical trial focusing on unfit acute myeloid leukemia (AML). The event will feature Syros management and Dr. Daniel Pollyea from the University of Colorado, highlighting the trial's initial findings and future plans. Initial data will also be presented at the 64th American Society of Hematology Annual Meeting on the same date. Participants can register for the event and access a live webcast.

Syros Pharmaceuticals (NASDAQ:SYRS) announced that CEO Nancy Simonian, M.D., will speak at the Piper Sandler 34th Annual Healthcare Conference on November 30 at 4:00 p.m. ET, held at The Lotte New York Palace. Management will also engage in one-on-one meetings. A live webcast of the presentation will be accessible on the Syros website, with an archived replay available for 30 days. Syros focuses on innovative small molecules for gene expression control and is advancing a clinical-stage pipeline that includes therapies for various cancers.

Syros Pharmaceuticals (SYRS) has successfully closed a merger with TYME Technologies, raising approximately $190 million, enhancing its cash balance to $245 million, which extends its cash runway into 2025. The company reported third-quarter revenues of $3.9 million, down from $5.7 million year-over-year, with a net loss of $30.3 million. Encouraging data from the safety lead-in portion of its SELECT-AML-1 Phase 2 trial and initial results from the SY-5609 trial in pancreatic cancer patients were announced, reinforcing the potential of its therapies.

Syros Pharmaceuticals (NASDAQ:SYRS) plans to host a live conference call and webcast on November 14, 2022, at 8:30 a.m. ET, to discuss its third quarter 2022 financial results. The call will provide updates on the company's clinical-stage pipeline, including treatments for conditions such as myelodysplastic syndrome and acute myeloid leukemia. Participants can register for the call here and access the webcast on Syros' website.